Navigation Links
Phase 3 Open-Label Study Comparing Tapentadol Extended Release Tablets to Oxycodone Controlled Release Tablets Published by Pain Practice
Date:7/19/2010

ratory depression with carbon dioxide retention. Therefore, NUCYNTA® should not be used in patients susceptible to the effects of raised cerebrospinal fluid pressure such as those with head injury and increased intracranial pressure. Opioid analgesics may obscure the clinical course of patients with head injury due to effects on pupillary response and consciousness. NUCYNTA® should be used with caution in patients with head injury, intracranial lesions, or other sources of preexisting increased intracranial pressure.

NUCYNTA® is a mu-opioid agonist and is a Schedule II controlled substance. Such drugs are sought by drug abusers and people with addiction disorders. Diversion of Schedule II products is an act subject to criminal penalty. NUCYNTA® can be abused in a manner similar to other mu-opioid agonists, legal or illicit. This should be considered when prescribing or dispensing NUCYNTA® in situations where the physician or pharmacist is concerned about an increased risk of misuse and abuse. All patients treated with mu-opioid agonists require careful monitoring for signs of abuse and addiction. NUCYNTA® may be abused by crushing, chewing, snorting or injecting the product. These practices pose a significant risk to the abuser that could result in overdose and death.

Experience with NUCYNTA® overdose is very limited. Management of overdose should be focused on treating symptoms of mu-opioid agonism. Primary attention should be given to reestablishment of a patent airway and institution of assisted or controlled ventilation when overdose of NUCYNTA® is suspected. Supportive measures (including oxygen and vasopressors) should be employed in the management of circulatory shock and pulmonary edema accompanying overdose as indicated. Cardiac arrest or arrhythmias may require cardiac massage or defibrillation.

Patients should be cautione
'/>"/>

SOURCE PriCara
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... , Oct. 2, 2014   Mast Therapeutics, ... announced today that Edwin L. Parsley , D.O. ... and Senior Vice President.  Dr. Parsley has ... Aires Pharmaceuticals, Inc. in February 2014.  He has served ... and as Chief Medical Officer of Aires since April ...
(Date:10/2/2014)...   Intarcia Therapeutics, Inc. today announced successful ... clinical trials for ITCA 650 (exenatide, delivered continuously once ... The first trial, FREEDOM-1, was a placebo-controlled, double-blind phase ... of ITCA 650 in patients with type 2 diabetes ... significantly superior to placebo for both 40 mcg and ...
(Date:10/1/2014)...   Plexus Information Systems, Inc. (Plexus ... Systems (AIMS), announced a partnership with NextGen ... subsidiary of Quality Systems, Inc. and a leading ... Logo - http://photos.prnewswire.com/prnh/20140930/149406 ... This partnership extends the NextGen Healthcare product portfolio ...
Breaking Medicine Technology:Mast Therapeutics Announces Appointment Of Chief Medical Officer 2Mast Therapeutics Announces Appointment Of Chief Medical Officer 3Mast Therapeutics Announces Appointment Of Chief Medical Officer 4Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 2Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 3Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 4Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 5Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 2Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 3
... Feb. 9, 2011 Reportlinker.com announces that ... in its catalogue: Global ... Plaque Treatment 2011 ... the responses of a comprehensive survey conducted ...
... 9, 2011 Reportlinker.com announces that a new ... Asia Pacific Markets for Orthopedic ... http://www.reportlinker.com/p0377965/Asia-Pacific-Markets-for-Orthopedic-Large-Joint-Reconstructive-Devices-2011.html In 2010, the ... Japan and South Korea were valued at over ...
Cached Medicine Technology:Reportlinker Adds Global Physician Survey on Stents, Stent-Grafts and Vulnerable Plaque Treatment 2011 2Reportlinker Adds Asia Pacific Markets for Orthopedic Large Joint Reconstructive Devices 2011 2
(Date:10/2/2014)... 1, 2014 (HealthDay News) -- Genes may interact with stress ... suggests. The genetic risk occurs in about 13 percent ... finding could help these people reduce their heart disease risk ... and stress management, the Duke University researchers said. The ... found a strong link between variations in the EBF1 gene ...
(Date:10/2/2014)... By Dennis Thompson ... -- A newborn,s risk of developing celiac disease isn,t reduced ... found in wheat called gluten to an infant,s diet help ... a pair of new studies in the Oct. 2 ... put to rest hopes that a child could avoid celiac ...
(Date:10/2/2014)... Dennis Thompson HealthDay ... Forty-two states and the District of Columbia now have a ... respiratory illness that has been infecting children since the ... with the virus have died in recent weeks, but it,s ... played in those deaths, officials said. Health officials are ...
(Date:10/1/2014)... small protein beta-amyloid is strongly associated with Alzheimer,s disease; ... this peptide is the causal agent of the onset ... such confirmation is that beta-amyloid is not harmful when ... is when it self-assembles to form the so-called amyloid ... target, beta-amyloid alone, but with multiple ones because each ...
(Date:10/1/2014)... human eye, the brain of a rat and a ... says a QUT leading robotics researcher. , Dr ... the new study uses new computer algorithms to enable ... tunnels. , "This is a very Frankenstein type of ... of a thing together because we,re taking the eyes ...
Breaking Medicine News(10 mins):Health News:Genes May Make Some More Prone to Heart Disease When Under Stress 2Health News:Infant's Early Diet Doesn't Change Celiac Disease Risk, Study Finds 2Health News:Infant's Early Diet Doesn't Change Celiac Disease Risk, Study Finds 3Health News:42 States Reporting Respiratory Virus That Targets Kids 2Health News:42 States Reporting Respiratory Virus That Targets Kids 3Health News:Laying siege to beta-amyloid, the key protein in Alzheimer's disease 2Health News:Robot researcher combines nature to nurture 'superhuman' navigation 2
... LeMond ... real-to-life road feel and performance output to ensure avid cyclists and triathletes stay in ... ... introduces the all-new Revolution bike trainer that delivers the industry,s most real-to-life ...
... ... get more exposure through free publicity and other low cost PR methods. , ... (PRWEB) July 2, 2010 -- ADPublishing.org LLC, ... guide which enables small business owners to generate their own free publicity. Online PR and ...
... ... C-rich , ... IL (PRWEB) July 2, 2010 -- There’s growing consumer awareness and concern in the U.S. ... children. This month (July 2010), European food and beverage manufacturers will be required to include ...
... routine for protection against infection when percutaneous endoscopic gastrostomy ... wall, is surgically inserted in the stomach. The new ... used today. The method, presented in the British ... 200 patients at the Karolinska University Hospital in Solna, ...
... ... Northwestern Health Sciences University to create an experienced team of chiropractic and medical professionals ... years old). , ... (PRWEB) July 2, 2010 -- University of Western States has partnered with Northwestern Health ...
... ... Templar cross architecture contains math codes that support frequency-based medicine. The idea ... paradigm that will change the face of future medicine. , ... (PRWEB) July 2, 2010 -- It usually ...
Cached Medicine News:Health News:As Real as It Gets: All-New LeMond Revolution Bike Trainer Delivers Incomparable Road Feel and Performance 2Health News:As Real as It Gets: All-New LeMond Revolution Bike Trainer Delivers Incomparable Road Feel and Performance 3Health News:Publishing and Media Distribution Firm Launches Online Public Relations Kit for Businesses Seeking Free Publicity 2Health News:Surf Sweets Among Few Candy Offerings Free of Synthetic Dyes Despite Growing Consumer Concern Over Affect on Children 2Health News:Surf Sweets Among Few Candy Offerings Free of Synthetic Dyes Despite Growing Consumer Concern Over Affect on Children 3Health News:Surf Sweets Among Few Candy Offerings Free of Synthetic Dyes Despite Growing Consumer Concern Over Affect on Children 4Health News:Simpler and cheaper antibiotic prophylaxis with insertion of nutrition catheter in the stomach 2Health News:Study Seeks Effective Treatment for Adolescent Low Back Pain 2Health News:Is Frequency the Future of Medicine or an Ancient Mystery Revealed? 2Health News:Is Frequency the Future of Medicine or an Ancient Mystery Revealed? 3Health News:Is Frequency the Future of Medicine or an Ancient Mystery Revealed? 4Health News:Is Frequency the Future of Medicine or an Ancient Mystery Revealed? 5
... (ECP) is a surgical approach to glaucoma ... laser application. The ciliary body (which produces ... from the anterior or posterior segment, through ... tissues are easily and accurately identified utilizing ...
... of German Craftsmanship have produced ... the world. Ocutek® now makes ... holders of the coveted Meisterbrief ... apprenticeship, are qualified to become ...
... Craftsmanship have produced the finest ... Ocutek® now makes them available ... the coveted Meisterbrief certificate, which ... qualified to become Ocutek instrument ...
... Centuries of German Craftsmanship have ... in the world. Ocutek now ... Only holders of the coveted ... eight-year apprenticeship, are qualified to ...
Medicine Products: